NZ506135A - Monocyte colony inhibitory factor (M-CIF) derivatives and their use in treating sepsis - Google Patents

Monocyte colony inhibitory factor (M-CIF) derivatives and their use in treating sepsis

Info

Publication number
NZ506135A
NZ506135A NZ506135A NZ50613597A NZ506135A NZ 506135 A NZ506135 A NZ 506135A NZ 506135 A NZ506135 A NZ 506135A NZ 50613597 A NZ50613597 A NZ 50613597A NZ 506135 A NZ506135 A NZ 506135A
Authority
NZ
New Zealand
Prior art keywords
inhibitory factor
cif
derivatives
monocyte colony
treating sepsis
Prior art date
Application number
NZ506135A
Other languages
English (en)
Inventor
Reiner L Gentz
Vikram Patel
Brent L Kreider
Jun Zhang
Michael Antonaccio
Donna Mendrick
Pablo Jimenex
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of NZ506135A publication Critical patent/NZ506135A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ506135A 1996-09-30 1997-09-30 Monocyte colony inhibitory factor (M-CIF) derivatives and their use in treating sepsis NZ506135A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2729996P 1996-09-30 1996-09-30
US2730096P 1996-09-30 1996-09-30

Publications (1)

Publication Number Publication Date
NZ506135A true NZ506135A (en) 2002-11-26

Family

ID=26702293

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ335003A NZ335003A (en) 1996-09-30 1997-09-30 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1)
NZ506135A NZ506135A (en) 1996-09-30 1997-09-30 Monocyte colony inhibitory factor (M-CIF) derivatives and their use in treating sepsis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ335003A NZ335003A (en) 1996-09-30 1997-09-30 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1)

Country Status (8)

Country Link
EP (1) EP0941330A1 (xx)
JP (1) JP2001500382A (xx)
KR (1) KR20030097607A (xx)
CN (1) CN1239510A (xx)
AU (1) AU4657697A (xx)
CA (1) CA2267193A1 (xx)
NZ (2) NZ335003A (xx)
WO (1) WO1998014582A1 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6488925B2 (en) 1993-12-22 2002-12-03 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polypeptides
US6451562B1 (en) 1993-12-22 2002-09-17 Human Genome Sciences, Inc. Polypeptides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) polynucleotides
US6001606A (en) * 1994-03-08 1999-12-14 Human Genome Sciences, Inc. Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6495129B1 (en) 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
AU777297B2 (en) * 1996-09-30 2004-10-07 Human Genome Sciences, Inc. Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1), monocyte colony inhibitory factor (M-CIF), and macrophage inhibitory factor-4 (MIP-4)
US6632425B1 (en) 1997-03-20 2003-10-14 Human Genome Sciences, Inc. Chemokine compositions
US6495128B1 (en) 1998-11-10 2002-12-17 Human Genome Sciences, Inc. Human chemokine β-7 deletion and substitution proteins
EP1142908A4 (en) * 1999-01-07 2002-05-22 Takeda Chemical Industries Ltd PROCESS FOR PRODUCING ACTIVATED PROTEINS
AU1083401A (en) * 1999-10-14 2001-04-23 Human Genome Sciences, Inc. Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1)
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
KR100867257B1 (ko) * 2001-10-09 2008-11-11 케모센트릭스, 인크. 포밀 펩티드 수용체 유사 1 수용체에 대한 리간드로유용한 조성물 및 이의 사용 방법
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
EP1675870A1 (en) * 2003-10-24 2006-07-05 IPF Pharmaceuticals GmbH Human chemokine hcc-1 polypeptides to improve stem cell transplantation
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
EP1738175A2 (en) * 2004-03-22 2007-01-03 Novartis AG Chemokine ccl18 as a biomarker
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
EP2208072B1 (en) * 2007-10-22 2015-07-01 St Vincent's Hospital Sydney Limited Methods of prognosis
CN113215085B (zh) * 2021-05-07 2024-05-10 澳门大学 一种脂类物质添加剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2214484T3 (es) * 1993-12-22 2004-09-16 Human Genome Sciences, Inc. Proteinas inflamatorias de macrofagos mip-3, mip-4 y mip-1 gamma.
US20030105293A1 (en) * 1993-12-24 2003-06-05 Wolf-Georg Forssmann Human circulating cytokine cc-1
US5602008A (en) * 1994-11-29 1997-02-11 Incyte Pharmaceuticals, Inc. DNA encoding a liver expressed chemokine
MX9708537A (es) * 1995-05-05 1998-02-28 Human Genome Sciences Inc Quimiocina beta-8 quimiocina beta-1 y proteina-4 inflamatoria de los macrofagos, humanas.
JPH11512610A (ja) * 1995-09-29 1999-11-02 スミスクライン・ビーチャム・コーポレイション 短縮形ケモカインβ−８
WO1997015594A1 (en) * 1995-10-24 1997-05-01 Smithkline Beecham Corporation Novel chemokine for mobilizing stem cells

Also Published As

Publication number Publication date
CN1239510A (zh) 1999-12-22
NZ335003A (en) 2000-11-24
WO1998014582A1 (en) 1998-04-09
JP2001500382A (ja) 2001-01-16
CA2267193A1 (en) 1998-04-09
KR20030097607A (ko) 2003-12-31
AU4657697A (en) 1998-04-24
EP0941330A1 (en) 1999-09-15

Similar Documents

Publication Publication Date Title
NZ506135A (en) Monocyte colony inhibitory factor (M-CIF) derivatives and their use in treating sepsis
TW336885B (en) Composite fuel element for smoking articles
CA2075060A1 (en) Novel vehicle gases and their use in medical preparations
TW430669B (en) A hybrid toxin fragment and their use
IL80883A0 (en) Process for altering the host range of bacillus thuringiensis toxins,and novel toxins produced thereby
AU8635391A (en) Nucleotide sequences coding for a human protein with angiogenesis regulative properties
CA2160131A1 (en) New Bacillus Thuringiensis Strains and Their Insecticidal Proteins
GB9014102D0 (en) Electrocatalyst for the oxidation of methane and an electrocatalytic process
DE3882593T2 (de) Polypeptid und dessen Herstellung.
AU7247087A (en) Injection with screw feed and subsequently gas pressure
ES8800016A1 (es) Un metodo para reducir el contenido de humedad del tabaco en particulas y un aparato secador correspondiente.
IL130123A0 (en) Mutants of the LAG-3 protein their expression and use
MY104393A (en) Azeotropic compositions of 1,1-dichloro-1- fluorethane and methanol/ethanol.
AU2978697A (en) Novel peptide, process for the production of the same, and use of the same
AU3498795A (en) Method of blocking the sec receptor
AU5192790A (en) Human elastase inhibitor
TW266183B (xx)
NZ230654A (en) Anti-cell proliferative penta and hexa peptides
IL76194A (en) 4,5-dihydro-4-oxo-2-((2-trans-phenyl cyclopropyl)amino)-3-furancarboxylic acids and derivatives
AU4499897A (en) Isolation and use of motoneuronotrophic factors
ZA945708B (en) Rye-flour
AU4852190A (en) Constant-boiling, azeotrope-like mixtures of dichlorotrifluoroethane, 1,1-dichloro-1-fluoroethane, and methanol and/or ethanol
ZA891463B (en) Bacillus thuringiensis genes,toxins and methods
MX9605402A (es) Nueva sustancia activa peptidica y su obtencion.
EP0501650A3 (en) Bacillus thuringiensis genes encoding novel coleopteranactive protein toxins

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)